IL-26 and Systemic Lupus Erythematosus

U

University Hospital, Strasbourg, France

Status

Terminated

Conditions

Diagnosis of Lupus According to ACR criteriaAgreement for the Blood Sampling

Study type

Observational

Funder types

Other

Identifiers

NCT01889641
5504

Details and patient eligibility

About

Treatment of multisystemic forms of lupus displays severe side effects and limited efficacy, underscoring the need to better dissection of the pathogenic mechanisms. Concordant with preliminary data, IL26 signaling could be impaired in systemic lupus. Moreover, IL 26 could be a marker of the disease activity and then a potential therapeutic target. In the present study, serum IL 26 level in lupus patients and control will be measured.

Enrollment

23 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • diagnostic of Lupus according to ACR criteria ( four criteria are necessary)
  • age > 18 years old

Exclusion criteria

treatment by cyclophosphamide, rituximab, belimumab in the year before inclusion study

Trial design

23 participants in 2 patient groups

Patients with lupus
Description:
Patients with lupus (four levels of activity disease)
healthy volunteers
Description:
Subjects controls

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems